CART-138 (Chinese PLA General Hospital)

N/A

Report date: 2024/06/01 20:00:05

Base Information

Drug NameCART-138 (Chinese PLA General Hospital)
Drug Alias Nameanti-CD138 CAR T-cell therapy (multiple myeloma)CART-133 cell therapyCD133-directed CAR T cells therapyanti-CD133-CAR vector-transduced T cells therapy
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionSyndecan-1 modulatorsWnt signalling pathway inhibitors
TargetsSyndecan-1
Therapy Area/IndicationsBrain NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPla General Hospital
Active IndicationsN/A
Inactive IndicationsBrain NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A